Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Johnson & Johnson, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Turnover Ratios
Inventory turnover 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Receivables turnover 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Payables turnover 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Working capital turnover 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Average No. Days
Average inventory processing period 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Add: Average receivable collection period 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Operating cycle 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Less: Average payables payment period 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Cash conversion cycle 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The analysis of short-term operating activity ratios indicates a general decline in operational efficiency over the observed period from April 2022 through March 2026. There is a consistent trend toward longer processing and collection cycles, which has extended the overall operating and cash conversion cycles.

Inventory Management
A steady deterioration in inventory efficiency is evident. The inventory turnover ratio decreased from 2.77 in April 2022 to 2.13 by March 2026. Consequently, the average inventory processing period expanded from 132 days to 172 days, suggesting a slower movement of goods and a potential increase in stockpiling or a decline in sales velocity.
Receivables Management
Receivables turnover exhibits a gradual downward trend, moving from 6.08 to 5.44 over the period. This decline is mirrored in the average receivable collection period, which rose from 60 days to 67 days. While less volatile than inventory metrics, this indicates a slight weakening in the efficiency of credit collections.
Payables Management
Payables turnover remained relatively volatile, starting at 3.26 and ending at 2.96. The average payables payment period fluctuated between 111 and 145 days, ending at 123 days in March 2026. These fluctuations suggest a dynamic approach to managing supplier obligations, with periodic extensions of payment terms to preserve liquidity.
Operating and Cash Conversion Cycles
The operating cycle, which combines the inventory processing and receivable collection periods, lengthened significantly from 192 days to 239 days. The cash conversion cycle followed a similar upward trajectory, increasing from 80 days in April 2022 to 116 days in March 2026, despite a temporary dip to 93 days in December 2025. This indicates that more capital is being tied up in the operating process for longer durations.
Working Capital Utilization
The working capital turnover ratio demonstrates extreme volatility, characterized by irregular spikes, most notably reaching 284.99 in June 2025 before settling at 66.14 in March 2026. Such drastic fluctuations typically suggest significant shifts in the net working capital base, potentially resulting from strategic corporate restructuring or substantial changes in the balance of current assets and liabilities.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Johnson & Johnson, inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Inventories 14,583 14,191 14,146 13,412 12,659 12,444 12,603 12,169 11,383 11,181 11,198 12,888 12,809 12,483 11,675 11,437 10,990
Short-term Activity Ratio
Inventory turnover1 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Merck & Co. Inc. 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Inventory turnover = (Cost of products soldQ1 2026 + Cost of products soldQ4 2025 + Cost of products soldQ3 2025 + Cost of products soldQ2 2025) ÷ Inventories
= (8,106 + 7,968 + 7,303 + 7,628) ÷ 14,583 = 2.13

2 Click competitor name to see calculations.


An analysis of operating activity reveals a persistent decline in inventory efficiency over the analyzed period. While the cost of products sold has experienced fluctuations and a subsequent recovery, inventory levels have grown at a faster rate, resulting in a diminished turnover ratio.

Inventory Turnover Ratio
A consistent downward trajectory is observed, with the ratio decreasing from 2.77 in April 2022 to 2.13 by March 2026. The most pronounced decline occurred between April 2022 and July 2023, after which the ratio largely fluctuated within a lower range of 2.08 to 2.46. This trend indicates a lengthening of the duration required to convert inventory into sales.
Inventory Valuation
Inventories exhibited a general upward trend, increasing from 10,990 million USD in April 2022 to 14,583 million USD by March 2026. Despite a temporary contraction during the second half of 2023, where levels dropped to a low of 11,181 million USD in December 2023, a steady and significant accumulation of stock occurred from early 2024 through the end of the period.
Cost of Products Sold (COPS)
The cost of products sold showed notable volatility, peaking at 7,919 million USD in July 2022 before declining to a low of 6,462 million USD in July 2023. From 2024 onward, a steady growth phase is evident, with the value reaching 8,106 million USD by March 2026. However, the increase in COPS was insufficient to offset the growth in inventory levels, contributing to the overall reduction in turnover efficiency.

AI Ask an analyst for more


Receivables Turnover

Johnson & Johnson, receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Accounts receivable, trade, less allowances 17,721 17,178 17,611 17,846 16,020 14,842 16,174 15,794 14,946 14,873 14,798 16,777 16,350 16,160 15,890 16,139 15,594
Short-term Activity Ratio
Receivables turnover1 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Merck & Co. Inc. 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Receivables turnover = (Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025) ÷ Accounts receivable, trade, less allowances
= (24,062 + 24,564 + 23,993 + 23,743) ÷ 17,721 = 5.44

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a general downward trend in receivables turnover efficiency over the period from April 2022 to March 2026. While the company maintained a relatively stable collection cycle in the early stages of the period, there is an observable shift toward lower turnover ratios, indicating a slower conversion of credit sales into cash.

Receivables Turnover Trajectory
The receivables turnover ratio peaked at 6.08 in April 2022 and experienced a gradual decline, reaching a period low of 5.08 by June 2025. Although intermittent recoveries occurred, such as the increase to 5.98 in December 2024, the overall trend indicates a reduction in the frequency with which accounts receivable are cleared during the annual cycle.
Revenue and Receivable Correlation
Sales to customers exhibited volatility, with a notable dip throughout 2023 before recovering to a peak of 24,564 million US$ in September 2025. However, the accounts receivable balance grew more aggressively in the later stages, rising from approximately 15,594 million US$ in April 2022 to 17,721 million US$ by March 2026. This growth in the receivables balance has outpaced the growth in sales, directly contributing to the compression of the turnover ratio.
Operational Efficiency Observations
A significant contraction in efficiency is observed in the first half of 2025, where the turnover ratio dropped to 5.08. This coincides with a sharp increase in trade receivables to 17,846 million US$. The subsequent stabilization around 5.44 by March 2026 suggests that while the extreme dip was corrected, the company has not returned to the higher efficiency levels observed in 2022.

AI Ask an analyst for more


Payables Turnover

Johnson & Johnson, payables turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of products sold 8,106 7,968 7,303 7,628 7,357 7,128 6,963 6,869 6,511 6,798 6,606 6,462 6,687 7,765 7,807 7,919 7,598
Accounts payable 10,460 11,991 9,625 9,464 9,545 10,311 8,954 8,848 8,174 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309
Short-term Activity Ratio
Payables turnover1 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Merck & Co. Inc. 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Payables turnover = (Cost of products soldQ1 2026 + Cost of products soldQ4 2025 + Cost of products soldQ3 2025 + Cost of products soldQ2 2025) ÷ Accounts payable
= (8,106 + 7,968 + 7,303 + 7,628) ÷ 10,460 = 2.96

2 Click competitor name to see calculations.


The payables turnover ratio exhibits a fluctuating pattern over the analyzed period, generally ranging between 2.52 and 3.29. A cyclical trend is evident, characterized by recurring declines in turnover efficiency during the final quarters of the calendar year, suggesting a seasonal shift in the management of supplier obligations.

Payables Turnover Volatility
The ratio reached its peak of 3.29 in October 2023, indicating a period of accelerated payment to suppliers. Conversely, the lowest point was recorded in December 2025 at 2.52. This variance suggests periodic adjustments in payment terms or changes in procurement timing.
Year-End Cyclicality
A consistent downward trend in the turnover ratio is observed every December (2.66 in 2022, 2.76 in 2023, 2.66 in 2024, and 2.52 in 2025). These troughs coincide with significant peaks in accounts payable balances, most notably the 11.99 billion USD recorded in December 2025, indicating a systematic increase in short-term liabilities at the close of the fiscal year.
Operational Cost and Liability Correlation
The cost of products sold experienced a contraction through 2023, reaching a low of 6.46 billion USD in July 2023, before entering a steady growth phase from March 2024 (6.51 billion USD) through March 2026 (8.11 billion USD). While operational costs increased, accounts payable did not follow a linear growth path, resulting in the observed fluctuations in the turnover ratio as the company balanced procurement growth with payment schedules.

AI Ask an analyst for more


Working Capital Turnover

Johnson & Johnson, working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets 59,173 55,624 54,611 54,498 71,551 55,893 53,249 57,817 57,002 53,495 53,703 60,567 64,388 55,294 65,236 63,847 60,424
Less: Current liabilities 57,716 54,126 50,869 54,180 56,903 50,321 51,759 53,933 48,725 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390
Working capital 1,457 1,498 3,742 318 14,648 5,572 1,490 3,884 8,277 7,213 9,333 6,397 4,015 (508) 19,693 19,026 17,034
 
Sales to customers 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Short-term Activity Ratio
Working capital turnover1 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Merck & Co. Inc. 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Working capital turnover = (Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025) ÷ Working capital
= (24,062 + 24,564 + 23,993 + 23,743) ÷ 1,457 = 66.14

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals significant volatility in working capital management relative to a stable revenue stream. While sales to customers remained consistent throughout the period, the working capital turnover ratio exhibited extreme fluctuations, driven primarily by sharp contractions in working capital.

Revenue Stability
Sales to customers maintained a consistent range, fluctuating between a low of 20,894 million USD in April 2023 and a high of 24,564 million USD in December 2025. This stability indicates a steady demand for products and a predictable top-line performance over the analyzed timeframe.
Working Capital Volatility
Working capital demonstrated erratic behavior, characterized by several sharp declines. A notable deficit of 508 million USD occurred in December 2022, followed by a recovery and subsequent instability. A significant trough was observed in June 2025, where working capital dropped to 318 million USD, representing a substantial decrease from the 14,648 million USD recorded in March 2025.
Working Capital Turnover Analysis
The turnover ratio transitioned from a stable range of 4.88 to 5.57 in 2022 to a highly volatile state in subsequent years. Because the ratio is sensitive to the denominator, the sharp reductions in working capital led to exponential spikes in turnover, most notably reaching 284.99 in June 2025 and exceeding 60.00 in late 2025 and early 2026. These peaks suggest periods where the organization operated with minimal net current assets relative to its sales volume.
Operational Efficiency Trends
The shift from a turnover ratio of approximately 5.0 in early 2022 to consistently higher figures—often exceeding 20.0 after 2023—indicates a fundamental change in the working capital structure. The trend suggests a strategic or situational move toward leaner operating liquidity, although the extreme variance in the ratio suggests inconsistency in the maintenance of short-term asset levels.

AI Ask an analyst for more


Average Inventory Processing Period

Johnson & Johnson, average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Inventory turnover 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Short-term Activity Ratio (no. days)
Average inventory processing period1 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Merck & Co. Inc. 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.13 = 172

2 Click competitor name to see calculations.


The analysis of operating activity indicates a consistent decline in inventory management efficiency between April 2022 and March 2026. There is a clear inverse correlation between the turnover rates and the duration of the inventory processing cycle, suggesting a slowdown in the movement of goods.

Inventory Turnover Performance
A sustained downward trajectory is observed in the inventory turnover ratio, which decreased from a high of 2.77 in April 2022 to 2.13 by March 2026. This trend indicates a diminishing capacity to cycle through inventory stocks. Although a temporary increase to 2.46 was noted in October 2023, the overall movement reflects a progressive reduction in turnover velocity.
Average Inventory Processing Period
The average inventory processing period demonstrates a corresponding upward trend, expanding from 132 days in April 2022 to 172 days by March 2026. The processing duration reached its peak of 176 days in September 2025. This extension signifies that inventory is remaining in the system for significantly longer durations before being sold.
Operational Implications
The increase in the processing period by 40 days over the analyzed timeframe suggests a potential accumulation of unsold stock or a shift in supply chain dynamics. The convergence of the turnover ratio at 2.13 during the final two quarters indicates that the decline in efficiency has reached a plateau, establishing a new, slower baseline for operating activity.

AI Ask an analyst for more


Average Receivable Collection Period

Johnson & Johnson, average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Receivables turnover 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Short-term Activity Ratio (no. days)
Average receivable collection period1 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Merck & Co. Inc. 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.44 = 67

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a general decline in the efficiency of receivables management from April 2022 through March 2026. This trend is characterized by a gradual decrease in the receivables turnover ratio and a corresponding extension of the average collection period.

Receivables Turnover Trends
The turnover ratio exhibits a downward trajectory, starting at 6.08 in April 2022 and reaching a period low of 5.08 in June 2025. Although temporary recoveries occurred, such as a peak of 5.98 in December 2024, the overall trend indicates a reduction in the frequency with which the company converts its receivables into cash.
Average Receivable Collection Period
The collection period reflects a widening gap in cash realization, moving from an initial 60 days in early 2022 to a peak of 72 days in June 2025. The data shows a period of relative stability during 2022, followed by a steady increase throughout 2023 and 2024, suggesting a slowing of the cash conversion cycle.
Period Stabilization and Final Observations
Following the peak in mid-2025, the collection period appears to have stabilized, remaining constant at 67 days through March 2026. This represents a net increase in the collection cycle of approximately 11.7% compared to the initial 60-day baseline established at the start of the observed period.

AI Ask an analyst for more


Operating Cycle

Johnson & Johnson, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Short-term Activity Ratio
Operating cycle1 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Merck & Co. Inc. 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 172 + 67 = 239

2 Click competitor name to see calculations.


The overall operating cycle exhibits a sustained upward trajectory over the analyzed period, expanding from 192 days in April 2022 to 239 days by March 2026. This expansion indicates a longer duration between the initial outlay for inventory and the final collection of cash from sales, signaling a reduction in short-term operational efficiency.

Average Inventory Processing Period
A significant and consistent increase is observed in the inventory processing period, which rose from 132 days in April 2022 to 172 days in March 2026. The peak occurred in September 2025 at 176 days. This trend suggests a slowing of inventory turnover, which may be attributed to increased stock holdings or a deceleration in product movement.
Average Receivable Collection Period
The receivable collection period demonstrated more stability than inventory, although a slight upward trend is evident. Starting at 60 days in April 2022, the period fluctuated and reached a maximum of 72 days in June 2025 before settling at 67 days by March 2026. This indicates that while cash collection from customers remains relatively controlled, there has been a marginal increase in the time required to convert receivables into cash.
Operating Cycle Drivers
The expansion of the operating cycle is primarily driven by the lengthening of the inventory processing period. The increase of 40 days in inventory processing over the period is the dominant factor contributing to the total 47-day extension of the operating cycle, whereas the receivable collection period contributed only 7 days to the overall increase.

AI Ask an analyst for more


Average Payables Payment Period

Johnson & Johnson, average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Payables turnover 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Short-term Activity Ratio (no. days)
Average payables payment period1 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Merck & Co. Inc. 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.96 = 123

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a cyclical pattern in the management of trade payables, characterized by recurring fluctuations in both turnover rates and the average duration of payment cycles.

Payables Turnover Trends
The payables turnover ratio exhibits a fluctuating trend, generally ranging between 2.52 and 3.29. A consistent downward trend is observed during the final quarter of each calendar year, with notable lows recorded in December 2022 (2.66), December 2023 (2.76), December 2024 (2.66), and December 2025 (2.52). Peaks in turnover are typically observed in the first and third quarters, indicating a more rapid settlement of obligations during these intervals.
Average Payables Payment Period Analysis
The average payables payment period demonstrates a strong inverse correlation with turnover, with durations fluctuating between a minimum of 111 days and a maximum of 145 days. A clear seasonal extension of payment terms is evident at year-end, with peaks occurring every December. The most significant extension was recorded in December 2025, reaching 145 days, while the shortest payment cycles were observed in October 2023 (111 days) and March 2024 (113 days).
Working Capital Observations
The data suggests a systemic tendency to extend payment terms toward the end of the fiscal year. This pattern indicates a strategic increase in the utilization of supplier credit to bolster short-term liquidity in the fourth quarter, followed by a contraction of the payment period in the subsequent quarters to normalize vendor relations and obligations.

AI Ask an analyst for more


Cash Conversion Cycle

Johnson & Johnson, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Average receivable collection period 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Average payables payment period 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Short-term Activity Ratio
Cash conversion cycle1 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Merck & Co. Inc. 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 172 + 67123 = 116

2 Click competitor name to see calculations.


The operating activity ratios indicate a general deterioration in working capital efficiency over the analyzed period, with the cash conversion cycle expanding from 80 days in April 2022 to 116 days by March 2026.

Average Inventory Processing Period
A persistent upward trend is observed in the inventory processing period, which rose from 132 days to 172 days. This steady increase represents the most significant factor contributing to the lengthening of the cash conversion cycle, suggesting a decline in inventory turnover efficiency.
Average Receivable Collection Period
The collection period remains relatively stable, fluctuating between a minimum of 60 days and a maximum of 72 days. While there is a slight upward drift beginning in 2023, the impact of receivable collection on the overall cash cycle is minimal compared to inventory movements.
Average Payables Payment Period
Payment periods exhibit high volatility, with values ranging from 111 to 145 days. Frequent fluctuations are evident, particularly with periodic spikes toward the end of calendar years, which serve to temporarily shorten the cash conversion cycle by delaying cash outflows to suppliers.
Cash Conversion Cycle Trends
The overall cash conversion cycle demonstrates a general trajectory of increase, peaking at 127 days in September 2025. The expansion of this cycle indicates that a greater amount of working capital is tied up in the operating process for longer durations, potentially limiting short-term liquidity.

AI Ask an analyst for more